文献速递抗栓抗凝管理药物不良反应与药物警戒

凝血酶原复合物减少心脏移植术中血制品使用

Prothrombin Complex Concentrate Reduces Blood Product Utilization in Heart Transplantation.
PubMed 文献 · Pharmacotherapy · 2017-01-01

BACKGROUND: Current practices for the reversal of warfarin before cardiac surgery include the use of vitamin K and fresh frozen plasma (FFP) to reduce the risk of bleeding.…

要点

  • 4-F PCC组术前24小时接受血制品比例10% vs 对照组56%(p<0.001)。
  • 术中4-F PCC组浓缩红细胞中位数3 vs 7单位(p<0.001),FFP中位数4 vs 9单位(p<0.001)。
  • 术后48小时4-F PCC组接受血制品比例24% vs 对照组51%(p=0.04)。

核心结论

  • 4-F PCC与心脏移植术前24小时及术中血制品使用减少相关。
  • 单中心研究显示4-F PCC显著减少术前FFP逆转华法林的需求。

研究设计与样本

  • 收集术前24小时、术中及术后48小时的血制品使用情况。

主要发现

  • 术前24小时,4-F PCC组2例(10%)接受血制品,对照组22例(56%)(p<0.001)。
  • 术中所有患者均接受血制品,4-F PCC组浓缩红细胞中位数3单位 vs 对照组7单位(p<0.001),FFP中位数4单位 vs 9单位(p<0.001)。
  • 术后48小时,4-F PCC组5例(24%)接受血制品,对照组20例(51%)(p=0.04)。

临床怎么用

  • 心脏移植术前需逆转华法林时,可考虑使用4-F PCC以减少血制品使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current practices for the reversal of warfarin before cardiac surgery include the use of vitamin K and fresh frozen plasma (FFP) to reduce the risk of bleeding. Although the 2010 International Society of Heart and Lung Transplantation guidelines acknowledge the use of prothrombin complex concentrate (PCC), there is no clear consensus on its efficacy. The objective of this study was to assess the efficacy of four-factor (4-F) PCC administration in patients requiring warfarin reversal before heart transplantation by determining blood product utilization perioperatively. METHODS: Twenty-one patients who received 4-F PCC for warfarin reversal before heart transplantation were compared to a similar cohort of 39 patients who did not receive 4-F PCC, from January 2011 to July 2015. Blood product utilization was collected retrospectively for the 24-hour preoperative, intraoperative, and 48-hour postoperative periods. RESULTS: Patients receiving 4-F PCC required fewer blood products in all three time periods. In the 24-hour preoperative period, 22 (56%) patients in the control group and 2 (10%) patients in the 4-F PCC groups received blood products (p<0.001). Intraoperatively, all patients received blood products. The 4-F PCC group required fewer units of packed red blood cells (median 3 vs 7 units, p<0.001) and FFP (median 4 vs 9 units, p<0.001). In the 48-hour postoperative period, 20 (51%) patients in the control group and 5 (24%) patients in the 4-F PCC group received blood products (p=0.04). CONCLUSIONS: 4-F PCC is associated with reduced blood product utilization 24 hours preoperatively and intraoperatively. Historically, the majority of patients require FFP for warfarin reversal preoperatively. In this single-center study, a significant reduction in the need for FFP was demonstrated with the use of 4-F PCC.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Enter DH, Zaki AL, Marsh M, et al. Prothrombin Complex Concentrate Reduces Blood Product Utilization in Heart Transplantation. Pharmacotherapy. 2017. PMID: 28833357. doi:10.1002/phar.2015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。